CN1303238A - 提供谷氨酰胺的方法 - Google Patents
提供谷氨酰胺的方法 Download PDFInfo
- Publication number
- CN1303238A CN1303238A CN99806599A CN99806599A CN1303238A CN 1303238 A CN1303238 A CN 1303238A CN 99806599 A CN99806599 A CN 99806599A CN 99806599 A CN99806599 A CN 99806599A CN 1303238 A CN1303238 A CN 1303238A
- Authority
- CN
- China
- Prior art keywords
- alimentation composition
- lactalbumin
- glutamine
- purposes
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 109
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 150000001413 amino acids Chemical class 0.000 claims abstract description 32
- 102000004407 Lactalbumin Human genes 0.000 claims description 33
- 108090000942 Lactalbumin Proteins 0.000 claims description 33
- 150000002632 lipids Chemical class 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 9
- 238000004088 simulation Methods 0.000 claims description 9
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 206010022998 Irritability Diseases 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims 1
- 150000004668 long chain fatty acids Chemical class 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 abstract description 40
- 235000016709 nutrition Nutrition 0.000 abstract description 19
- 102000007544 Whey Proteins Human genes 0.000 abstract description 11
- 108010046377 Whey Proteins Proteins 0.000 abstract description 11
- 235000021119 whey protein Nutrition 0.000 abstract 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 63
- 235000013305 food Nutrition 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 241000700159 Rattus Species 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 230000035764 nutrition Effects 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 12
- 239000000413 hydrolysate Substances 0.000 description 11
- 108010068370 Glutens Proteins 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000005862 Whey Substances 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000003642 hunger Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010044422 Peptamen Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000532467 Aletes Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- QEYGHMMVEWKRBD-VLHUMFRXSA-N C(CC)N[C@@H](CCO)C(=O)O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound C(CC)N[C@@H](CCO)C(=O)O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO QEYGHMMVEWKRBD-VLHUMFRXSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 108010063123 alfare Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PNMUAGGSDZXTHX-UHFFFAOYSA-N glycyl-glutamine Chemical compound NCC(=O)NC(C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108060006613 prolamin Proteins 0.000 description 1
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Seasonings (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
公开了为患者提供谷氨酰胺的方法。包括乳清蛋白或或模拟乳清蛋白氨基酸分布型的蛋白混合物作为蛋白源的一种营养组合物,可经肠道给予所述患者。所述乳清蛋白可以是水解的乳清蛋白。所述患者可以是应激性患者、早产婴儿或运动员。
Description
本发明涉及为人类和动物提供谷氨酰胺的方法,如以维持或提高血浆中的谷氨酰胺浓度。本发明也涉及治疗需要补充谷氨酰胺的人和动物的方法,并涉及提高人类和动物体内谷氨酰胺储备的方法。
在机体内,氨基酸谷氨酰胺具有许多重要功能。例如,它作为将氨基氮从骨骼肌转移至内脏器官的主要载体,作为胃肠道和免疫系统中快速分裂细胞的燃料,作为允许肾脏排泄酸性负荷并保护机体免遭酸中毒的底物。而且,越来越多的证据显示,谷氨酰胺对宿主防御机制适当地起作用和伤口愈合是必需的。
尽管有这些功能,谷氨酰胺传统上被当作非必需氨基酸,原因是机体一般能够由谷氨酸盐和谷氨酸合成足够的谷氨酰胺用于其需求。同时,谷氨酰胺是机体血液和游离氨基酸库中含量最多的氨基酸。然而,这一点只有在机体健康时才成立,且不适合于早产婴儿。在机体患病期间,谷氨酰胺代谢作用速度加快,而机体不能合成足够的谷氨酰胺以满足需要,特别是在应激反应发生时更是这样,如脓毒病、伤害、烧伤、炎症、腹泻和外科手术。当应激反应发生时,胃肠道、免疫细胞,炎症组织和肾脏对谷氨酰胺的消耗量显著增加,该消耗速度远超过谷氨酰胺的内部合成速度。当谷氨酰胺明显缺乏时,组织功能改变和形态学上的改变将表现出来,并出现负氮平衡。相似地,早产婴儿机体合成谷氨酰胺的速度较慢,谷氨酰胺经常不能满足需要。而且,发现运动员在剧烈运动后血浆中谷氨酰胺浓度下降。
将谷氨酰胺补充食物给予应激反应期间的早产婴儿或给予运动员,结果将改善他们的健康状况。比如,现已表明,谷氨酰胺补充食物能使粘蛋白和肠上皮再生,支持消化道屏障功能,缩短住院时间,改善免疫功能,并提高患者存活率(Stehle et al 1989;Lancet,1:231-3;Hannerqvist et al;1989;Ann.Surg;209,455-461;Li et al;1995;J.Parenter. Enteral Nutr.,18,303-307和Gianotti等人;1995;J.Parenter.Enteral Nutr.,19,69-74)。因此,现在认为谷氨酰胺是危重病人和其他应激性患者的条件必需氨基酸(Lacey et al;1990;Nutrition Review,48:297-309)。
处于应激反应时对谷氨酰胺的额外需求必须来自外源物质,比如饮食。然而,传统上人们没有补充配有谷氨酰胺的营养配制食品,因为人们认为谷氨酰胺是非必需氨基酸,而且谷氨酰胺仅微溶于水,更重要的是它在水溶液中相对不稳定。为解决这个稳定性问题,有人建议补充含有L-谷氨酰胺的粉状配制食品。这些配制食品在给予前立即复水。然而,该方法对肠道配制食品并不很成功,因为游离态的谷氨酰胺在被吸收前由于胃酸的作用而转变为焦谷氨酸盐。同时保健专家更喜欢即可消费的液体配制食品,而不喜欢粉状配制食品。
补充含谷氨酰胺饮食其他方法集中于使用谷蛋白或谷蛋白水解产物为营养组合物的蛋白源。谷蛋白中富含谷氨酰胺,因而是谷氨酰胺的好来源。而且,使用谷蛋白或谷蛋白水解产物提供的优点是提供稳定且相对可溶形式谷氨酰胺。然而,谷蛋白具有潜在致敏性,这严重限制它用于营养组合物。使用谷蛋白水解产物代替谷蛋白可以在一定程度上缓解这个问题。基于谷蛋白水解产物的营养组合物市面上已有销售,商品名是NutricompImmum,Reconvan和Glutasorb。然而,尽管致敏反应的危险已大大减弱,但并未完全消除。
一个更进一步的方法是补充含合成的二肽(如L-丙氨酰-L-谷氨酰胺或L-甘氨酰-L-谷氨酰胺)营养配制食品。这些二肽在溶液中稳定,已表明是谷氨酰胺补充物的有效形式。然而,这种特性的合成二肽将大大提高营养配制食品的成本。
因此,需要一个能为有需求的患者提供谷氨酰胺的可接受的方法。
相应的,一方面,本发明为给哺乳动物提供谷氨酰胺提供了一个方法。该方法包括将营养组合物经肠道给予哺乳动物,该组合物包含乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物为蛋白源。
我们惊奇地发现,包含乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物为蛋白源的营养组合物,提高人类和动物机体中的血浆谷氨酰胺浓度,尽管乳清蛋白包含相对少量的谷氨酰胺。此外,包含乳清蛋白为蛋白源的营养组合物所提供谷氨酰胺的浓度大大高于那些包含游离氨基酸为蛋白源的营养组合物所提供的浓度。
所述人类或动物患者最好是应激性患者、早产婴儿或运动员。应激性患者的实例如危重病患者,或患有脓毒病、伤害、烧伤和炎症的患者,或外科手术后正在恢复的患者。
另一方面,本发明提供了提高哺乳动物肌肉中谷氨酰胺浓度的方法,该方法包括经肠道给予哺乳动物有效量的营养组合物,该组合物包含乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物为蛋白源。
再一方面,本发明提供了改善肠受伤、患病或发育不良的哺乳动物肌的谷氨酰胺状态、或维持肠生理功能的方法,该方法包括经肠道给予哺乳动物有效量的营养组合物,该组合物包含乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物为蛋白源。
哺乳动物可以是早产婴儿。
本发明的实施方案目前只通过实施例进行描述。本发明是基于这样的发现的,即由肠道给予一种包含乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物为蛋白源的营养组合物,结果将提高血浆谷氨酰胺浓度。这使得该组合物对营养性控制哺乳动物谷氨酰胺浓度非常有用。
该蛋白源中的乳清蛋白可以是完整的蛋白或水解蛋白,或完整蛋白和水解蛋白的混合物。若有需求,蛋白源可以进一步包含一定量的其他适宜类型的蛋白质。比如,所述蛋白源还可以含少量的酪蛋白、大豆蛋白、稻蛋白、豌豆蛋白、角豆蛋白、燕麦蛋白、酪蛋白-大分子糖肽(glyco-macropeptide),或这些蛋白的混合物。而且,若想要,蛋白源中还可包含一定量的游离氨基酸。其他适宜类型的蛋白质优选占所述蛋白源的20%(重量)以下,更优选多时于蛋白源的10%(重量)。也可以提供模拟乳清蛋白氨基酸分布型的蛋白源。比如,所述蛋白源可以包含约80%至90%(重量)的酪蛋白,约0.5%至2%(重量)的异亮氨酸,约2%至8%(重量)的亮氨酸、约1%至5%(重量)的半胱氨酸和约1%至5%(重量)的赖氨酸。
然而,所述蛋白源优选包含或者乳清蛋白水解产物,或基于甜性乳清或基于酸性乳清。乳清蛋白水解产物特别适合于患有胃肠功能受危害、吸收不良或不耐受的患者。乳清蛋白水解产物可以通过本领域众所周知的技术步骤生产。另一方面,包含乳清蛋白水解产物的营养组合物可以在市场上购得。例如,包含乳清蛋白水解产物的临床营养组合物可以购自NestléNutrition Company,商标是PEPTAMEN,或购自Nutrition Medical,Inc,商标是PROPEPTIDES。同样,包含乳清水解产物的婴儿营养组合物可购自NestléAlete GmbH,商标是ALFARE。
给婴儿使用,乳清蛋白水解产物最好还含有游离氨基酸精氨酸、酪氨酸和组氨酸。
给成人使用,最好是用水解程度大约为10%至20%的乳清蛋白水解产物。在本说明书中,“水解程度”(DH)是指氨基酸中氮的含量与总氮含量相比的百分数,它衡量了蛋白质的水解程度。水解程度约为10%至20%的乳清蛋白水解产物包含少于约5%的游离氨基酸,包含约15%至55%的分子量小于1000Da的肽、约20%至55%的分子量为1000Da至5000Da的肽和约15%至35%的分子量大于5000Da的肽。
给成年人使用,蛋白源最好提供约占营养组合物能量的约10%至20%的能量。例如,蛋白源可以提供营养组合物能量的约15%至18%的能量。给婴儿使用,蛋白源最好为营养组合物的约30%至50%(干重)。例如,足月婴儿的配制食品中,蛋白源可以为营养组合物的约8%至20%(干重)。此外对于早产婴儿的配制食品,蛋白源可以为营养组合物的约15%至25%(干重)。
营养组合物也可以包含碳水化合物源。给成人使用,碳水化合物源最好提供约占营养组合物能量的35%至65%的能量;特别是提供占营养组合物能量的40%至60%的能量。例如,碳水化合物源可以提供约占组合物能量的51%的能量。给婴儿使用,碳水化合物优选为营养组合物的约35%至70%(干重),更优选为约45%至65%(干重)。可以使用几种碳水化合物,包括麦芽糊精、玉米淀粉、改性淀粉、乳糖或蔗糖或以上物质的混合物。该组合物最好不含乳糖。
组合物中还可包含脂质源。给成年人使用,脂质源最好提供约占营养组合物能量的20%至50%的能量;特别是提供约占营养组合物能量的25%至40%的能量。例如,脂质源可以提供约占营养组合物能量的33%的能量。给婴儿使用,脂质源最好为营养组合物的约15%至35%(干重),特别是营养组合物的约20%至30%(干重)。例如,脂质源可以为营养组合物的约26%(干重)。
脂质源可以包含中等链甘油三酯(MCT)和长链甘油三酯(LCT)的混合物。若包含MCT,则脂质源最好包含至少约30%至80%(重量)的MCT。例如,MCT可以占脂质源的约70%(重量)。LCT的各种来源是向日葵油、红花油、油菜籽油、棕榈油、豆油、乳脂(milk fat)、玉米油和大豆卵磷脂。经分馏的椰子油是MCT的合适来源。
营养组合物中脂质的分布型可以设计为多不饱和脂肪酸omega-6(n-6)与omega-3(n-3)的比率约为1∶1至12∶1。例如,给成人使用,n-6与n-3的比率可以约为6∶1至9∶1;给婴儿使用,n-6与n-3的比率约为9∶1至11∶1。同样的,给婴儿使用的脂质源可以包含长链多不饱和脂肪酸,如花生四烯酸和廿二碳六烯酸。
营养组合物最好包含完全的维生素和矿物质分布型。例如,每1000卡热量的营养组合物可以提供充足的维生素和矿物质,以供给维生素和矿物质的推荐日用量的约50%至250%。
给成年人使用的营养组合物的含能量最好约为800kcal/l至1200kcal/l,例如含能量约为1000kcal/l。给婴儿使用的营养组合物的含能量最好约为600kcal/l至1000kcal/l,例如含能量约为650kcal/l至850kcal/l。
营养组合物可以为合适的形式。例如,营养组合物可以为可溶性粉剂、液体浓缩物或即可饮用的制剂形式。或者,营养组合物可以为固体形式,例如为即食排或早餐谷类。特别优选即可饮用的制剂。可以通过鼻管(nasogastric tube)、空肠管,或让患者饮用或食用,为患者喂食所述组合物。也可以存在各种调味剂、纤维、甜味剂和其它添加剂。
营养组合物可以由常规方法生产。例如,可以通过将蛋白源、碳水化合物源和脂质源混合,制备所述营养组合物。如果使用该法,可以在掺混料中包括乳化剂。维生素和矿物质可以于此时加入,但通常于之后加入,以避免热降解。任何亲脂维生素、乳化剂以及诸如此类的物质可以在混合之前溶于脂质源中。然后,最好混入经反渗透的水以形成液体混合物。适宜的水温约为50℃至80℃,以帮助所述成分分散。市场上能买到的液化器可用于配制液体混合物。
然后,液体混合物可经热处理以减少细菌量。例如,快速将液体混合物加热到约80℃至110℃并保持5秒钟至5分钟。这一操作可通过蒸汽通入或换热器完成,例如使用板式换热器。
然后,可将液体混合物冷却至约60℃至85℃例如通过急骤冷却。然后将液体混合物均化,如经过两个阶段均化,第一阶段压力约为7MPa至40Mpa,第二阶段压力约为2MPa至14MPa。然后可将该均化混合物进一步冷却以添加热敏感的成份,如维生素和矿物质。该均化混合物的pH值和固体含量适宜在此时标准化。
若要生产粉状营养组合物,则将均化混合物转移至合适的干燥器上,如喷雾干燥器或冻干干燥器,以转变为粉末。粉末中的含水量应该少于5%(重量)。若要生产液态营养组合物,则最好将均化混合物无菌分装入合适的容器。容器的无菌分装可以这样进行:先预热均化混合物,如预热至约75℃至85℃;然后,向均化混合物注入蒸汽以升高温度至约140℃至160℃,如约150℃;然后,冷却均化混合物至约75℃至85℃,如采用急聚冷却;然后均化该均化混合物,进一步冷却至室温并分装入容器中。具有该特性的无菌分装的合适仪器可在市场上买到。
该营养组合物可用作营养支持,尤其是为动物和人类提供营养和谷氨酰胺。特别是该营养组合物可以为应激性患者提供营养和谷氨酰胺,所述患者例如为危重患者,或患有脓毒病、受伤、烧伤和炎症的患者,或者外科手术后正在恢复的患者。更进一步地,该营养组合物可用于为肠道受伤害或患病的患者提供谷氨酰胺,或维持肠道的生理功能。而且,该营养组合物可用于提高人类和动物血浆中谷氨酰胺的浓度。
该营养组合物可为剧烈训练后的运动员和早产婴儿提供谷氨酰胺。
必须认识到,尽管该营养组合物计划主要用于需要补充谷氨酰胺的患者,但是它也可作为那些没有患病的人的营养来源。
该营养组合物可以成为专用营养源或成为其他营养源的补充物,包括非肠胃给予的营养物。
患者对该营养组合物的需求量将根据诸如患者的健康状况、患者的体重和年龄及该营养组合物是否是专用营养源等因素而变化。然而,医师可容易地确定需求量。一般而言,足够的营养组合物给予量为患者提供每天每公斤体重约1g至4.0g蛋白。例如,可给予危重患者的成人每天每公斤体重约1.5g至2.0g蛋白,可以给予早产婴儿每天每公斤体重约2.0g至4.0g蛋白,而可给予婴儿每天每公斤体重约2.0g至3.0g蛋白。而且,对应激性患者,最好给予足够的该营养组合物,为其提供每天约10g至25g的谷氨酰胺。可以分多剂服用该营养组合物,如3至5剂,以补充每日需求量,也可一次服用。或者,可以连续供给患者该营养组合物。
现在描述本发明的具体实施例以进一步说明本发明。实施例1
一种适用于提高患者血浆中谷氨酰胺浓度的等渗液体食物,可从NestléClinical Nutrition获得。该食物商标为PEPTAMEN,它的成分如下:
营养物 | 每1000ml含量 |
蛋白质(水解甜乳清) | 40g |
碳水化合物(麦芽糊精、玉米淀粉) | 127 |
脂质(中等链甘油三酯、向日葵油、大豆卵磷脂) | 39 |
维生素A | 4000IU |
维生素D | 280IU |
维生素E | 28IU |
维生素K | 80μg |
维生素C | 140mg |
硫胺素 | 2mg |
核黄素 | 2.4mg |
烟酸 | 28mg |
维生素B6 | 4mg |
叶酸 | 540μg |
泛酸 | 14mg |
维生素B12 | 8μg |
生物素 | 400μg |
胆碱 | 450mg |
牛磺酸 | 80mg |
L-肉碱 | 80mg |
矿物质钙、磷、镁、锌、铁、铜、锰、碘、钠、钾、氯化物、铬、钼、硒 |
该食物的能量密度为1000kcal/l,其中蛋白质提供16%的能量,碳水化合物提供51%的能量,脂质提供33%的能量。谷氨酰胺约占蛋白源的6.2%(重量)。实施例2ⅰ)检验食物:
以下的食物用于检验:
食物 | 组成 | 蛋白源 | 谷氨酰胺含量(g/100g) |
1 | 95%的实施例1组合物和5%的纤维素 | 水解乳清 | 6.2 |
2 | 95%的PROPEPTIDES制品和5%的纤维素 | 水解乳清 | 5.42 |
A | 95%的VIVONEX PLUS制品和5%的纤维素 | 游离氨基酸 | 21.63 |
B | 95%REABLAN制品和5%的纤维素 | 水解酪蛋白和乳清 | 8.09 |
对照 | 大豆蛋白分解物、蔗糖、葡萄糖、纤维素、玉米淀粉、玉米油、维生素和矿物质 | 大豆 | 8.99 |
VIVONEX PLUS制品可由Sandoz Nutrition AG获得,REABILAN制品可由NestléClinical Nutrition获得。ⅱ)检验分析步骤:
通过用20μl包含磺基水杨酸(400mg/ml)和维生素C(60mg/ml)的溶液脱去200μl血浆中的蛋白质,分析血浆中的氨基酸。将混合物以10,000g离心3分钟,将D-葡糖氨酸(glycosaminic acid)和S-(2-氨基甲基)-L-半胱氨酸·HCl作为内标加入上清液中,并将上清于-80℃冻存直至分析为止。使用Beckman 6300氨基酸分析仪进行分析。为避免谷氨酰胺降解,所有样品在分析之前均于10℃保存。根据氨基酸各自的峰面积、外标和内标计算出氨基酸的浓度。
通过将100mg肌肉与冰冷的三氯乙酸(10%w/v)溶液混合,并于10,000rpm均化1分钟,分析肌肉的中谷氨酰胺。然后将混合物于4℃10,000g离心10分钟。将D-葡糖氨酸作为内标加入上清液中,并将上清液于-80℃冻存直至分析为止。使用Beckman 6300氨基酸分析仪进行分析。为避免谷氨酰胺降解,所有样品于分析之前均于10℃保存。根据氨基酸各自的峰面积、外标和内标可计算出氨基酸的浓度。ⅲ)检验步骤:
使用56只重约200g的Wistar雄性大鼠。大鼠于23℃饲养于分开的笼子中,采用12小时黑暗循环。它们可自主饮水,食用对照食物。
大鼠食用对照食物维持3天。到第四天,供给每只大鼠的对照食物的量限制为其前三天的消耗量的80%。大鼠每天饲喂一次,到第七天,将大鼠放入代谢笼中,并按体重将其随机分为7组,每组8只。其中一组为对照组,以对照食物维持生活。其余组的鼠饥饿72小时。所有的大鼠都可自主饮水。
当饥饿时间终了时,在麻醉下,从对照饥饿组每只大鼠的眼睛中抽取共1ml血样。然后按上述分析步骤分析血样中的血浆氨基酸。然后处死该组的大鼠,并将其胫骨肌取出于-80℃保存,直至用上述方法分析肌肉中谷氨酰胺时止。
将剩下的试验大鼠放入新的代谢笼中,再次按体重随机分为5组,每组8只。
然后,这5组大鼠各饲喂不同的实验性食物。食物如下:
组别 | 食物 |
对照再饲喂 | 对照 |
1 | 1 |
2 | 2 |
A | A |
B | B |
所述鼠饲喂3天。这三天结束时,在麻醉下从每组的每只大鼠的眼睛中抽取1ml血样,然后按前述分析步骤分析血样中氨基酸浓度。然后,处死这些大鼠,并取出胫骨肌。这些肌肉用于由前述方法分析肌肉中的谷氨酰胺浓度。ⅳ)检验结果:
血浆谷氨酰胺浓度如下:
组别 | 食品 | 谷氨酰胺摄入量(μmol/l) | 血浆谷氨酰胺(μmol/l) | 肌肉谷氨酰胺(μmol/l) |
对照组 | 对照组 | 733 | 829.1 | 4 |
对照饥饿组 | 对照组 | - | 758.6 | 2.7 |
对照再饲喂组 | 对照组 | 734 | 742.5 | 3.6 |
1 | 1 | 392 | 1025 6 | 5.3 |
2 | 1 | 336 | 1031.1 | 4.9 |
A | A | 1501 | 738.7 | 3.3 |
B | B | 424 | 881.7 | 3.9 |
结果表明,以基于乳清蛋白的食物食物1和食物2饲养的大鼠,其血浆谷氨酰胺浓度比其他大鼠的至少高出25%。尽管喂食食物1和食物2的大鼠从食物中接受的谷氨酰胺较少;而且远少于游离氨基酸食物A。同样的,该结果表明,以食物1和食物饲养的大鼠的肌肉谷氨酰胺浓度较高;就食物1来说,显著高于对照组的。
而且,就体重的增加、食物转化效率、存留氮转化为消化氮、存留氮转化为吸收氮及蛋白效率比而论,饥饿后,饲喂食物1和2的大鼠恢复得更好。
Claims (10)
1.乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物的用途,即用作制备可经肠道给予的营养组合物的蛋白源,所述营养组合物用于提高应激性哺乳动物血浆谷氨酰胺浓度。
2.乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物的用途,即用作制备可经肠道给予的营养组合物的蛋白源,所述营养组合物用于提高哺乳动物肌肉谷氨酰胺浓度。
3.乳清蛋白或模拟乳清蛋白氨基酸分布型的蛋白混合物的用途,即用作制备可经肠道给予的营养组合物的蛋白源,所述营养组合物用于为肠受伤害、患病或发育不良的哺乳动物提供谷氨酰胺。
4.根据权利要求3的用途,其中所述哺乳动物是肠道发育不良的早产婴儿。
5.根据权利要求4的用途,其中所述乳清蛋白是水解的,且所述蛋白源还包含精氨酸、酪氨酸和组氨酸。
6.根据权利要求1的用途,其中所述乳清蛋白是水解的乳清蛋白。
7.根据权利要求6的用途,其中所述水解的乳清蛋白包含低于约5%(重量)的游离氨基酸、约15%至55%(重量)的分子量小于1000Da的肽、约20%至55%的分子量为1000Da至5000Da的肽和约15%至35%(重量)的分子量大于5000Da的肽。
8.根据权利要求1-3中任一项的用途,其中所述蛋白源提供营养组合物能量的约10%至20%。
9.根据权利要求1-3中任一项的用途,其中所述营养组合物还包含提供约营养组合物能量的20%至50%的脂质,所述脂质包含中等链和长链脂肪酸的混合物。
10.根据权利要求1-3中任一项的用途,其中所述营养组合物还包括提供约营养组合物能量的35%至65%的碳水化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98201016 | 1998-03-31 | ||
EP98201016.7 | 1998-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1303238A true CN1303238A (zh) | 2001-07-11 |
CN1134227C CN1134227C (zh) | 2004-01-14 |
Family
ID=8233542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998065994A Expired - Fee Related CN1134227C (zh) | 1998-03-31 | 1999-02-22 | 提供谷氨酰胺的方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8178487B2 (zh) |
EP (1) | EP1065947B1 (zh) |
CN (1) | CN1134227C (zh) |
AT (1) | ATE237957T1 (zh) |
AU (1) | AU3142099A (zh) |
BR (1) | BR9909234A (zh) |
CA (1) | CA2326148C (zh) |
DE (1) | DE69907170T2 (zh) |
DK (1) | DK1065947T3 (zh) |
ES (1) | ES2195555T3 (zh) |
HK (1) | HK1039729A1 (zh) |
ID (1) | ID27818A (zh) |
PT (1) | PT1065947E (zh) |
WO (1) | WO1999049741A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104039174A (zh) * | 2012-01-09 | 2014-09-10 | N·V·努特里奇亚 | 用于早产婴儿的富含谷氨酰胺的营养组合物 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0114419D0 (en) * | 2001-06-13 | 2001-08-08 | Mars Uk Ltd | Health food |
US6864230B2 (en) | 2001-07-31 | 2005-03-08 | Novartis Nutrition Ag | Glutamine rich dietary composition |
CA2489942A1 (en) * | 2002-07-01 | 2004-01-08 | Unilever Plc | Satiety inducing composition |
JP4970694B2 (ja) * | 2002-12-02 | 2012-07-11 | 株式会社明治 | 持続性筋肉疲労改善剤 |
CN100356876C (zh) * | 2005-09-30 | 2007-12-26 | 北京康比特威创体育新技术发展有限公司 | 一种促进运动疲劳恢复的饮料 |
DE102006018293A1 (de) | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
WO2007143794A1 (en) * | 2006-06-15 | 2007-12-21 | Murray Goulburn Co-Operative Co. Limited | Formulation comprising whey protein and hydrolysates for improving muscle recovery |
RU2010119238A (ru) * | 2007-10-14 | 2011-11-27 | Юниверсити Оф Флорида Рисерч Фаундейшн Инк. (Us) | Состав для улучшения функции желудочно-кишечного тракта |
EP2165713B1 (en) * | 2008-09-19 | 2012-11-14 | Nestec S.A. | Whey and thymus function |
US10869843B2 (en) * | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
BR112015020977A2 (pt) | 2013-03-08 | 2017-07-18 | Axiom Foods Inc | suplemento de proteína de arroz e métodos de uso do mesmo |
WO2015034984A1 (en) | 2013-09-05 | 2015-03-12 | Emory University | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto |
WO2015154251A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
WO2018209131A1 (en) | 2017-05-12 | 2018-11-15 | Axiom Foods, Inc. | Rice products and systems and methods for making thereof |
US11058139B2 (en) * | 2018-07-03 | 2021-07-13 | Kerri Ann Langhorne | Recovery supplement for horses |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2459620B1 (fr) * | 1979-06-26 | 1983-08-05 | Agronomique Inst Nat Rech | Hydrolisat enzymatique total de proteines de lactoserum, obtention et application |
FI904074A7 (fi) * | 1989-08-28 | 1991-03-01 | Milupa Ag | Optimoidun aminohappokoostumuksen omaavat proteiini-, peptidi- ja aminohapposeokset sekä niiden käyttö keskosten ja rintalasten ravinnon sekä äidinmaidon lisäaineiden valmistamiseksi |
JP2907603B2 (ja) * | 1991-09-09 | 1999-06-21 | 雪印乳業株式会社 | 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品 |
JPH07255398A (ja) * | 1994-03-16 | 1995-10-09 | Snow Brand Milk Prod Co Ltd | 保存安定性及び嗜好性の高い経口経腸栄養組成物 |
US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
US5661123A (en) * | 1995-01-17 | 1997-08-26 | Nestec, Ltd. | Enteral composition for malabsorbing patients |
DE19717195C2 (de) * | 1997-04-24 | 2001-09-27 | Reichenauer Feil Andrea | Instantpulver und daraus herstellbares Getränk |
US5849335A (en) | 1997-06-02 | 1998-12-15 | Nestec S.A. | Composition and method for providing glutamine |
EP1123013A1 (en) | 1997-06-02 | 2001-08-16 | Société des Produits Nestlé S.A. | Product and method for providing glutamine |
US6019999A (en) | 1997-12-03 | 2000-02-01 | Miller; David F. | Process for making liposomal ion-exchange whey protein and products thereof |
US6051236A (en) | 1998-11-12 | 2000-04-18 | Pacifichealth Laboratories, Inc. | Composition for optimizing muscle performance during exercise |
US20020044988A1 (en) * | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
-
1999
- 1999-02-22 AU AU31420/99A patent/AU3142099A/en not_active Abandoned
- 1999-02-22 DK DK99913195T patent/DK1065947T3/da active
- 1999-02-22 ID IDW20001947A patent/ID27818A/id unknown
- 1999-02-22 AT AT99913195T patent/ATE237957T1/de not_active IP Right Cessation
- 1999-02-22 BR BR9909234-4A patent/BR9909234A/pt not_active IP Right Cessation
- 1999-02-22 CN CNB998065994A patent/CN1134227C/zh not_active Expired - Fee Related
- 1999-02-22 EP EP99913195A patent/EP1065947B1/en not_active Expired - Lifetime
- 1999-02-22 WO PCT/EP1999/001274 patent/WO1999049741A1/en active IP Right Grant
- 1999-02-22 CA CA002326148A patent/CA2326148C/en not_active Expired - Fee Related
- 1999-02-22 DE DE69907170T patent/DE69907170T2/de not_active Expired - Lifetime
- 1999-02-22 ES ES99913195T patent/ES2195555T3/es not_active Expired - Lifetime
- 1999-02-22 PT PT99913195T patent/PT1065947E/pt unknown
-
2002
- 2002-02-25 HK HK01108933A patent/HK1039729A1/xx not_active IP Right Cessation
-
2008
- 2008-11-24 US US12/277,037 patent/US8178487B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104039174A (zh) * | 2012-01-09 | 2014-09-10 | N·V·努特里奇亚 | 用于早产婴儿的富含谷氨酰胺的营养组合物 |
Also Published As
Publication number | Publication date |
---|---|
US20090075862A1 (en) | 2009-03-19 |
AU3142099A (en) | 1999-10-18 |
CA2326148C (en) | 2008-01-29 |
WO1999049741A1 (en) | 1999-10-07 |
CN1134227C (zh) | 2004-01-14 |
HK1039729A1 (en) | 2002-05-10 |
EP1065947B1 (en) | 2003-04-23 |
CA2326148A1 (en) | 1999-10-07 |
PT1065947E (pt) | 2003-08-29 |
US8178487B2 (en) | 2012-05-15 |
DE69907170T2 (de) | 2004-03-11 |
DK1065947T3 (da) | 2003-07-14 |
DE69907170D1 (de) | 2003-05-28 |
ATE237957T1 (de) | 2003-05-15 |
BR9909234A (pt) | 2000-11-28 |
ID27818A (id) | 2001-04-26 |
ES2195555T3 (es) | 2003-12-01 |
EP1065947A1 (en) | 2001-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1134227C (zh) | 提供谷氨酰胺的方法 | |
EP0705542B1 (en) | Adolescent dietary composition | |
CA2371696C (en) | Composition for an infant formula having a low threonine content | |
EP1535520B1 (en) | Infant formula containing prebiotic additive | |
DK2249666T3 (en) | Protein-rich liquid enteral nutritional composition on a casein basis | |
CA2133783C (en) | Enteral nutritional composition | |
CN1122457C (zh) | 为糖尿病人提供营养的组合物和方法 | |
RU2390269C2 (ru) | Применение молочной смеси для детского питания с пониженным содержанием белка | |
US11412768B2 (en) | Method of improving tolerance to hypoallergenic infant formulas | |
NO340945B1 (no) | Næringsmessig komplett morsmelkerstatning | |
RU2598707C2 (ru) | Детская смесь для применения в профилактике сердечно-сосудистых заболеваний | |
CA2347172A1 (en) | Protein material for slow digestion and its use | |
US5849335A (en) | Composition and method for providing glutamine | |
AU2020257046A1 (en) | Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate | |
CN113194750A (zh) | 用于在婴儿或幼儿中引起饱腹感、更好的睡眠和/或限制夜间觉醒的营养组合物 | |
WO2013109367A1 (en) | Reduced calorie infant formulas containing specific whey to casein ratios | |
JP2750467B2 (ja) | ペプチド混合物及び経腸栄養組成物 | |
TWI472300B (zh) | 包含核苷酸及/或類胡蘿蔔素之低卡路里嬰兒配方於降低後續生命中不利健康效應之用途 | |
Pure | IgG Pure™ | |
MXPA00009647A (en) | Method for providing glutamine | |
JP2001231496A (ja) | 栄養組成物 | |
SK283846B6 (sk) | Hypoalergénna výživa s redukovaným obsahom antigénov | |
MXPA01003794A (en) | Protein material for slow digestion and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040114 Termination date: 20180222 |